Androgen independent progression in prostate cancer: Risk factors

Author： Auzanneau C. Irani J. Dahmani L. Ouaki F. Pires C. Dore B.

Publisher： Elsevier

ISSN： 1569-9056

Source： European Urology Supplements, Vol.2, Iss.1, 2003-02, pp. : 26-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer

By Benaim E.A. Pace C.M. Lam P.M. Roehrborn C.G.

Urology, Vol. 59, Iss. 1, 2002-01 ,pp. : 73-78

Elsevier

Access to resources Recommend Favorite

Predictive factors of biochemical progression in prostate cancer patients treated with intermittent androgen suppression

By de la Taille A. Zerbib M. Conquy S. Amsellem-Ouazana D. Thiounn N. Flam T. Saighi D. Debre B.

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 135-135

Elsevier

Access to resources Recommend Favorite

Phase II study of docetaxel and estramustine in metastatic androgen-independent prostate cancer

By Guimaraes T. Bento M.J. Pinho T. Guedes d.C.R. Pinto F.

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 159-159

Elsevier

Access to resources Recommend Favorite

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer

By Vaishampayan U. Fontana J. Du W. Hussain M.

Urology, Vol. 60, Iss. 6, 2002-12 ,pp. : 1050-1054

Elsevier

Access to resources Recommend Favorite

Acid phosphatase: defining a role in androgen-independent prostate cancer

By Steineck G. Kelly W.K. Mazumdar M. Vlamis V. Schwartz M. Scher H.I.

Urology, Vol. 47, Iss. 5, 1996-05 ,pp. : 719-726

Elsevier

Access to resources Recommend Favorite